[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-344869-105":59,"doc-detail-344869-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","quantifying-rate-limiting-genetic-variation-in-breast-and-ovarian-tumourigenesis","Quantifying rate-limiting genetic variation in breast and ovarian tumourigenesis","","Genetic determinants required to initiate breast and ovarian cancer remain unclear, particularly whether BRCA1/2-related tumourigenesis is driven chiefly by point mutations or by copy-number changes. A statistical framework extending incidence–mutation models estimates the minimal driver events using somatic mutation and copy-number data from over 3000 TCGA and METABRIC tumours matched by subtype. Deletions, not SNVs, emerge as the likely rate-limiting events, with early recurrent loss events on chromosomes 13q and 17.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/quantifying-rate-limiting-genetic-variation-in-breast-and-ovarian-tumourigenesis/344869/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/quantifying-rate-limiting-genetic-variation-in-breast-and-ovarian-tumourigenesis/344869.png","ImageObject",300,407,{"name":92,"@type":93},"Olivia Brown","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-04","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":44},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What question does the study address about BRCA1/2-related tumourigenesis?","Question",{"text":112,"@type":113},"It tests whether tumour initiation is limited primarily by point mutations or by copy-number alterations, which remains uncertain for breast and ovarian cancer.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What did the modeling show about the types of rate-limiting genetic events?",{"text":117,"@type":113},"Deletions were identified as likely rate-limiting events, while SNVs alone could not explain observed incidence ratios.",{"name":119,"@type":110,"acceptedAnswer":120},"Which deletion events were highlighted as early and recurrent?",{"text":121,"@type":113},"The study reports early recurrent deletions involving chromosomes 13q and 17, accumulating more rapidly in BRCA1/2 carriers than in sporadic tumours.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},344869,1790211733,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":44,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},16904993612988,"https://ap-avatar.wpscdn.com/davatar_a8503ba1806abce46bf441b54a3ca4cd","Articles  \nQuantifying rate-limiting genetic variation in breast and ovarian tumourigenesis  \nKathleen E. Houlahan,a,b,c,d,e,f,g,h,s Mahad Bihie,g,s Yves Greatti,i,s Julián Grandvallet Contreras,j Daniel J. Fulop,k Gonzalo Lopez,k Marc Williams,l Hsin-Hsiung Huang,m Peter Van Loo,n,o Paul C. Boutros,a,b,c,d,e,p,q,r,∗ and Kuan-lin Huangk,∗∗,s  \naDepartment of Human Genetics, University of California, Los Angeles, Los Angeles, CA, USA bDepartment of Medical Biophysics, University of Toronto, Toronto, Canada  \ncJonsson Comprehensive Cancer Center, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA  \ndInstitute for Precision Health, University of California, Los Angeles, Los Angeles, CA, USA eVector Institute, Toronto, Canada  \nfDepartment of Medicine, Stanford University School of Medicine, Stanford, CA, USA gDepartment of Biochemistry and Biomedical Sciences, McMaster University, Hamilton, ON, Canada hCentre for Discovery in Cancer Research, McMaster University, Hamilton, ON, Canada  \niJohns Hopkins University, Baltimore, USA  \njDepartment of Pediatrics, University of Colorado Anschutz Medical Campus, Aurora, CO, USA  \nkDepartment of Genetics and Genomic Sciences, Department of Artificial Intelligence and Human Health, Center for Transformative Disease Modeling, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA  \nlMemorial Sloan Kettering Cancer Center, New York, USA  \nmDepartment of Statistics, University of Central Florida, Orlando, FL, USAnThe Francis Crick Institute, London, UK  \noDepartment of Genetics, The University of Texas MD Anderson Cancer Center, Houston, TX, USApDepartment of Pharmacology and Toxicology, University of Toronto, Toronto, Canada qDepartment of Urology, University of California, Los Angeles, Los Angeles, CA, USA  \nrSanford Burnham Prebys Medical Discovery Institute, La Jolla, CA, USA  \nSummary  \nBackground The number and type of genetic alterations required to initiate breast and ovarian cancer remain unclear. While germline BRCA1/2 carriers show markedly elevated cancer risk, it is uncertain whether point mutations or copy number alterations constitute the rate-limiting events of tumourigenesis.  \nMethods We developed a statistical framework extending prior incidence–mutation models to estimate the minimal number and type of driver events required for cancer initiation. Somatic mutation and copy-number data from >3000 breast and ovarian cancers in TCGA and METABRIC were compared between germline BRCA1/2 carriersand non-carriers matched on subtypes. Results were validated through analyses of evolutionary timing data, as well as single-cell whole genome sequencing (scWGS) data of genetically-engineered and patient-derived cancer/ pre-cancerous cells.  \nFindings Deletions, rather than single-nucleotide variants (SNVs), emerged as the likely rate-limiting events. Modeling indicated that 1–3 deletions are sufficient to initiate tumourigenesis, whereas SNVs alone could not explain observed incidence ratios. BRCA1/2-driven and sporadic tumours converged on similar deletion profiles, including early recurrent deletions of chromosomes 13q and 17, though carriers accumulated them more rapidly.  \nInterpretation Deletion-associated chromosomal instability likely represents the central trigger for breast and ovarian cancer initiation. These results explain why certain somatic driver mutations detected in normal tissues may not predict malignant progression, and that early detection strategies should instead prioritize testing deletions as potential biomarkers.  \nFunding NIH/NCI (P30CA016042; 1U01CA214194-01), NIH NIGMS (R35GM138113, 2R35GM138113), ACS (RSG- 22-115-01-DMC), CIHR Vanier Fellowship, and the Francis Crick Institute with core funding from Cancer Research UK, UK Medical Research Council, and Wellcome Trust.  \n*Corresponding author. UCLA Department of Human Genetics, BOX 957088, 57200A South Tower CHS, Los Angeles, CA, 90095, USA. ","cbCaij6cR1EsQcfj","https://ap.wps.com/l/cbCaij6cR1EsQcfj","pdf",4134370,18,"English","# Background\n# Methods\n# Results\n# Findings\n# Interpretation\n# Funding\n# Research in context\n## Evidence before this study\n## Added value of this study\n## Implications of all the available evidence\n# Introduction","[{\"question\":\"What question does the study address about BRCA1/2-related tumourigenesis?\",\"answer\":\"It tests whether tumour initiation is limited primarily by point mutations or by copy-number alterations, which remains uncertain for breast and ovarian cancer.\"},{\"question\":\"What did the modeling show about the types of rate-limiting genetic events?\",\"answer\":\"Deletions were identified as likely rate-limiting events, while SNVs alone could not explain observed incidence ratios.\"},{\"question\":\"Which deletion events were highlighted as early and recurrent?\",\"answer\":\"The study reports early recurrent deletions involving chromosomes 13q and 17, accumulating more rapidly in BRCA1/2 carriers than in sporadic tumours.\"}]","Quantifying rate-limiting genetic variation in breast and ovarian tumourigenesis | PDF",1790055500,45,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b1a35088d3d8ba1edbbd3a47b39c1648.webp",983,1310,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f00ca84b8d1a5ae95ba8629219bf8097.webp",982,1309,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/1946f47aa4b667caa30a1e18c1d4280e.webp",981,1308,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b55ff94c341b7571f8318a66ee244444.webp",980,1306]